CAPN11

Across TCGA pan-cancer cohorts, CAPN11 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CAPN11 data layer compared with 22 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CAPN11 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CAPN11 expression acts as an unfavorable survival marker, although some lineages such as LUAD and GBM show a favorable association.

LUAD, CCRCC, and GBM are the cancer types where CAPN11 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	III,IV	0.845	0.402	.002	17	view →
CCRCC	OS	Quartile	III,IV	0.737	1.000	.008	7	view →
GBM	OS	Median	All	0.672	0.368	.005	5	view →
PDAC	DFS	Quartile	II,III,IV	0.229	0.457	.024	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CAPN11–LUAD (DFS)

Open the LUAD breakdown →